OnConova Therapy Reports Financial Performance throughout the year

Nasdaq ontx, INC. As of 12 months, December 31, 2020, and providing business updates. The highlights of the 2020th quarter and the recent weeks include: • 123300, ONCONOVA’s proprietary multi-kinase inhibitor, Customs clearance of stage 1 research from the US Food and Drug Administration (FDA) • 123300 also received agency review committee (IRB) in a U. ratification S. Clinical Trial Web Site • Lasting 123300, the physical tumor study is underway, and continues to register patients • Raise $ 35 net income.

Two million equity products; cash and cash equivalents as of February 28, 2021, are about $ 49. 5 million • Starting research with independent investigators of oral rigosertib and the PD-1 inhibitor combination of non-small cell lung cancer of advanced KRAS mutations to consider the change of the company’s capital structure will be re-discussed in April On the 1st, 2021Management comments .The fourth quarter and recent weeks were actively effective in Nasdaq ontx at https://www.webull.com/quote/nasdaq-ontx because we continue to rise at 123300 to lead products, Stevenwheat · Fruit said,  D. ONCONOVA President and CEO and CEO. We submit a new drug application for the FDA for the treatment of advanced cancers in the previous stage, including HR + / her 2-metastatic breast cancer patient resistance approved the second generation CDK 4/6 inhibitor. 2020 In December, we received the FDA license and started research. Since our first website, IRB approval. We hope that the first patient will register in the second quarter of this year. The other two websites are in the research setting process.

This stage 1 studies the safety, tolerance, and pharmacokinetics of the oral administration, to 50 mg of drug kinetics at an increase of 40 mg of medicinal kinetics. We are in China’s partner Hank drug, in two The 123300 phase of the location, continued to collect similar patient populations in the 1 phase of the dose upgrade study.

The initial dose queue has been completed, and the second dose queue is registering. We are very happy that 123300 seems to be unable to batch tolerance because there is no dose limit toxic to date. Hanks studied in a 21-day cycle. Overall, the US and China No. 1 study expects to provide data on the safety curve of 123300 and may provide preliminary efficacy signals for patients with advanced cancer.

Comment on continuous investigators sponsoring and oral rigosertib, the company’s RAS path suppression factors added: We are currently supporting research on investigators to launch, these studies are exploring cancer driven by RAS gene mutation using oral rigosertib’s research No. 1 During the study of PD-1 inhibitors, patients with a mutation of non-small cell lung cancer. This study is open and continues to register patients, which is an object to identify the recommended phase 2 dose and characterize the safety curve of combination therapy. The result is expected in 2021. Before investing, you can check more stocks like nyse uwmc at https://www.webull.com/quote/nyse-uwmc.

Leave a Comment